Adnexus

I-Therapeutix, Inc. Closes $15 Million Financing

...agement, more than 20 investment professionals, and current investments in more than 115 companies. Polaris-backed successes in life sciences include adnexus (sold to Bristol-Myers Squibb), Advanced Inhalation Research (sold to Alkermes), Alnylam Pharmaceuticals (ALNY), Glycofi (sold to Merck), Momenta Phar...

Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007

...viously announced Productivity Transformation Initiative, $230 million for acquired in-process research and development relating to the acquisition of adnexus and $275 million relating to an impairment of the company's investment in certain auction rate securities (ARS). As of December 31, 2007, the compan...

Biotech Finishes on a High in August, Burrill Report Says

... midpoint of the proposed $14-$16 price range. Its shares jumped 10.8% by the end of August. Eight companies added themselves to the IPO runway: -- adnexus Therapeutics, which is focused on discovering, developing, and commercializing the proprietary drug class called Adnectins. Adnexus' first pr...

Adnexus in Medical Technology

Adnexus Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) on Clinical Product Candidate, CT-322

...ncology in the United States, and in February 2007 adnexus announced interim results of an ongoing Phase 1 op...lerates Adnectin drug discovery and development. adnexus is the exclusive developer of Adnectins. adnexus solely owns the Adnectin patent estate that contro...

Adnexus in Biological Technology

Bristol-Myers Squibb to Acquire Adnexus Therapeutics

Bristol-Myers Squibb to Advance Biologics Strategy Through Targeted Biologics Acquisition PRINCETON, N.J. and WALTHAM, Mass., Sept. 24 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) and Adnexus(TM) Therapeutics announced today the companies have ...

Accuri Cytometers Completes $4 Million Series D Financing

...leantech. During the past two decades Flagship's principals have been involved as founders or investors in many highly successful ventures including: adnexus Therapeutics, Alere Medical, Aspect Medical, Celera Genomics, ChemGenics Pharmaceuticals, Color Kinetics, Cytyc, Helicos Biosciences, Hypnion, IDEXX, ...

Microbia, Inc. Names Alex Chu as Vice President of Process Development

...perience in bioprocess development and manufacturing to Microbia. He was most recently the vice president of manufacturing and process development at adnexus Therapeutics, Bristol-Myers Squibb. Prior to this, he held multiple scientific and management positions at Abbott Laboratories and Abbott BioResearch ...

Accuri Cytometers Completes $13 Million Series C Financing

...Cleantech. During the past two decades Flagship's principals have been involved as founders or investors in many highly successful ventures including: adnexus Therapeutics, Alere Medical, Aspect Medical, Celera Genomics, ChemGenics Pharmaceuticals, Color Kinetics, Cytyc, Helicos Biosciences, Hypnion, IDEXX, ...

Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team

...Irvine and his B.A. in Computer Science and Biochemistry from the University of California, Los Angeles. Dr. John Mendlein recently served as CEO of adnexus Therapeutics (a developer of a new class of protein therapeutics) from May 2005 until October 2007, at which time the privately-held, Boston based bio...

Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community

...n BioPharma company, Bristol-Myers Squibb seeks to reallocate resources to enable additional strategic acquisitions, such as the recent acquisition of adnexus Therapeutics, as well as pursue partnerships and other collaborative arrangements. These alliances should add to the company's innovative capabilities...